Plain-English translation of NCT06930703 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage research study testing , an oral medication, to see if it can help reduce pain and inflammation in people with sickle cell disease. Researchers want to find the right dose of the medication that works best and causes the fewest side effects. The study will compare the medication at three different doses against a placebo (a dummy pill with no active ingredient) to understand how well it works.
Sickle cell disease causes severe pain crises and ongoing inflammation that can be hard to manage with current treatments. This medication may offer a new way to reduce both pain and the inflammatory markers in the body that contribute to disease complications.
You likely qualify if…
You likely don't qualify if…
You will take either the medication or a placebo twice a day for four weeks. During this time, you'll need to avoid all cannabis use and attend study visits where researchers will check on you, take blood samples to measure inflammation markers, and track how you're feeling. The researchers will watch you closely during these four weeks to see if the medication helps reduce your pain and inflammation, and to make sure you're tolerating it well.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment target
~52 participants
Started
April 2025
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Susanna Curtis
Icahn School of Medicine at Mount Sinai
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.